Catalent invests $14 million at its Eberbach, Germany softgel facility

28 Apr 2019

Expansion includes two new softgel encapsulation lines dedicated to Catalent’s proprietary Vegicaps technology.

Work is underway to expand Catalent's integrated turnkey softgel capabilities at its facility in Eberbach, Germany.

Catalent invests $14 million at its Eberbach, Germany softgel facility

The $14-million expansion, which is scheduled to be completed by mid-2020, includes two new softgel encapsulation lines dedicated to Catalent’s proprietary Vegicaps technology. This addition is driven by the increased global demand for animal-free consumer health products, and these new lines will be completed by September 2019. The investment also includes new printing technology, a state-of-the-art vision inspection system, expansion of the facility’s softgel coating capabilities, and the addition of further packaging capacity.

“The Eberbach facility is our biggest softgel development and manufacturing facility in Europe with a capacity of more than 10 billion softgel capsules per year,” commented Raoul Bernhardt, General Manager of the Eberbach facility. “This investment reflects the importance of the site and will enable us to better serve our customers with increased volumes and turnkey services.”

In addition to these capital investments, the site is increasing its total production output by growing the workforce by more than 10% across Operations, Quality Control and related supporting functions.

The 360,000-sq ft facility offers integrated softgel manufacturing services which simplify supply chain management and deliver products faster to market. In addition to handling prescription pharmaceuticals, over-the counter pharmaceuticals, nutritional supplements, medical devices and animal health products, the facility also specializes in handling highly potent and cytotoxic compounds within an isolated, self-contained cytotoxic suite. This is the latest expansion at the facility with the most recent one dating to early 2015 when it was expanded to include additional softgel coating and blister packaging equipment.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more